Guidelines for prevention of febrile neutropenia;Orientações para a prevenção da neutropenia febril: Em doentes submetidos a quimioterapia

Acta Medica Portuguesa

Volumn 21, Issue 1-3, 2008, Pages 7-20

  Barroso, Sérgio ^a   Damasceno, Margarida ^b   Dinis, José ^c   Gervásio, Helena ^d   Da Luz, Ricardo ^e   Passos Coelho, J L ^e   Sá, Anabela ^f   Costa, Luís ^g   Rodrigues, Helena ^c   Andrade, Sofia ^h   Macedo, Ana ^h   Moital, Inês ^h  

^a Hospital do Espirito Santo   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^e INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^f Hospitais Universitários de Coimbra   (Portugal)

^g HOSPITAL DE SANTA MARIA   (Portugal)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 3; MILODISTIM; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; NEUTROPENIA; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW;

ANTINEOPLASTIC AGENTS; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC;

EID: 51349090566     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. GREIL R, JOST LM: ESMO Guidelines Task Force.ESMO recommendations for the application of hematopoietic growth factors. Ann Oncol 2005;16 Suppl 1:i80-2
2. AAPRO MS, CAMERON DA, PETTENGELL R et al and European Organisation for Research and Treatment of Cancer (EORTC): Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42(15):2433-53. Epub 2006 Jun 5
3. FONT A, MOYANO AJ, PUERTO JM et al: Increasing dose intensity of cisplatin-etoposide in advanced non-small-cell lung carcinoma: a phase III randomised trial of the Spanish Lung Cancer Group. Cancer 1999;85:855-863
4. MILLER KD, LOEHRER PJ, GONIN R, EINHORN LH: Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997;15:1427-31
5. WOLL PJ, HODGETTS J, LOMAX L, BILDET F, COURCHABERNAUD V, THATCHER N: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomised controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-9
6. CHEVALLIER B, CHOLLET P, MERROUCHE Y et al: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564-71
7. GISSELBRECHT C, HAIOUN C, LEPAGE E et al: Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997;25:289-300
8. SMITH TJ, KHATCHERESSIAN J, LYMAN GH et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187-205. Epub 2006 May 8
9. JADAD et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17(1):1-12
10. TIMMER-BONTE JN et al: Prevention of chemotherapy-induced febrile neutropenia by prophylatic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974-84
11. HOLMES FA, O'SHAUGHNESSY JA, VUKELJA S: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20(3):727-731
12. HOLMES FA et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13(6):903-9
13. GREEN MD, KOELBL H, BASELGA J et al and International Pegfilgrastim 749 Study Group: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14(1):29-35
14. VOGEL CL, WOJTUKIEWICZ MZ, CARROLL RR et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84
15. SEYMOUR AM, DE CAMPOS E, THATCHER N et al: A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Eur J Cancer 1995;31A(13-14):2157-63
16. TONER GC, SHAPIRO JD, LAIDLAW CR et al: Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.J Clin Oncol 1998;16(12):3874-9
17. JUAN O, CAMPOS JM, CARANANA V, SANCHEZ JJ, CASAN R, ALBEROLA V: A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia. Support Care Cancer 2001;9(4):241-6
18. JONES SE, KHANDELWAL P, MCINTYRE K et al: Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. J Clin Oncol 1999;17(10):3025-32
19. BEVERIDGE RA, MILLER JA, KALES AN et al: A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998;16(6):366-373
20. MAYORDOMO JI, RIVERA F, DIAZ-PUENTE MT et al: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87(11):803-8
21. HANSEN F, STENBYGAARD L, SKOVSGAARD T: Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer. Acta Oncol 1995;34(7):919-924
22. VON MINCKWITZ G, KÜMMEL S, DU BOIS A et al: On behalf of the German Breast Group: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2007; Sep 9
23. OZER H, MIRTSCHING B, RADER M et al: Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007;12(4):484-494
24. SIENA S, PICCART MJ, HOLMES FA, GLASPY J, HACKETT J, RENWICK JJ: A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10(3):715-724
25. STATHOPOULOS GP, DIMOU E, STATHOPOULOS J, XYNOTROULAS J: Therapeutic administration of pegfilgrastim instead of prophylactic use. Anticancer Res 2005;25(3c):2445-8
26. BURSTEIN HJ, PARKER LM, KESHAVIAH A et al: Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23(33):8340-7
27. PAPALDO P, LOPEZ M, MAROLLA P et al: Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;23(28):6908-18. Epub 2005 Aug 29
28. MAHER DW, LIESCHKE GJ, GREEN M et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121(7):492-501
29. MORRISON VA, WONG M, HERSHMAN D, CAMPOS LT, DING B, MALIN J et al: Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13(4):337-348
30. MEZA LA, GREEN MD, HACKETT JR, NEUMANN TA, HOLMES FA: Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. Pharmacotherapy 2003;23(11):1424-31
31. TSAVARIS N, KOSMAS C, GOUVERIS P: G-CSF in solid tumor chemotherapy: a tailored regimen reduces febrile neutropenia, treatment delays and direct costs. Med Sci Monit 2004;10(2):PI24-8
32. KOUMAKIS G, VASSILOMANOLAKIS M, BARBOUNIS V: Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncol 1999;56(1):28-35
33. RIBAS A, ALBANELL J, BELLMUNT J: Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 1996;14(5):573-580
34. FYLES AW, MANCHUL L, LEVIN W, ROBERTSON JM, STURGEON J, TSUJI D: Effect of filgrastim (G-CSF) during chemotherapy and abdomino-pelvic radiation therapy in patients with ovarian carcinoma. Int J Radiat Oncol Biol Phys 1998;41(4):843-7
35. MARTIN M, LLUCH A, SEGUI MA et al: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17(8):1205-12. Epub 2006 Jun 9
36. GARCIA-CARBONERO R, MAYORDOMO JI, TORNAMIRA MV et al: Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93(1):31-8
37. CRAWFORD J et al: Practice Guidelines in Oncology - Myeloid Growth Factors; v.1.2007.[online] 2007; [cited on 2007 December 7]; Available from URL: www.nccn.org
38. Neupogen®: Resumo das Características do Medicamento. Julho 2006
39. Neulasta®: Resumo das Características do Medicamento. Julho 2007